ProCE Banner Activity

Changes in the HIV Prevention Landscape and Implications for Australia: Insights From HIVR4P

Conference Coverage
Clinical Thought

Australia has yet to include long-acting injectables in its HIV prevention strategy, but insights from the 5th HIVR4P Conference highlight global experiences and solutions can guide successful implementation.

Released: November 20, 2024

Expiration: November 19, 2025

Share

Faculty

Sharon R. Lewin

Sharon R. Lewin, AO, FRACP, PhD, FAHMS

Director, The Peter Doherty Institute for Infection and Immunity
Melbourne Laureate Professor and Head, Department of Infectious Disease
The University of Melbourne
Consultant Physician
Royal Melbourne and Alfred Hospitals
Melbourne, Australia

Provided by

Provided by Clinical Care Options, LLC in partnership with the International AIDS Society  

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare

Partners

IAS

ProCE Banner

Disclosure

Primary Author

Sharon R. Lewin, AO, FRACP, PhD, FAHMS

Director, The Peter Doherty Institute for Infection and Immunity
Melbourne Laureate Professor and Head, Department of Infectious Disease
The University of Melbourne
Consultant Physician
Royal Melbourne and Alfred Hospitals
Melbourne, Australia

Sharon R. Lewin, AO, FRACP, PhD, FAA, FAHMS: consultant/advisor/speaker: AbbVie, Esfam, Gilead, Merck, ViiV.